Century Therapeutics, Inc. (NASDAQ:IPSC), featuring a year-to-date gain of 114.11% and upside potential of 134.70%, secures a spot on our list of hot biotech stocks under $5 to buy. New preclinical ...

Human induced pluripotent stem cells (iPSCs) have a great potential for scientific and medical applications. They are used in research laboratories to model human diseases, helping to uncover ...

Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...

A research team at National Taiwan University has developed a new stem cell-based vaccine that could help prevent and treat colorectal cancer. Their research demonstrates that iPSC-based vaccines can ...

From the discovery of the Yamanaka factors to late-stage clinical trials, induced pluripotent stem cells have revolutionized biomedical science. For the first time, scientists reprogrammed cells from ...